Alpha Cognition Inc. ("Alpha Cognition", or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a strong note, ...

H.C. Wainwright initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $20 price target Alpha is an emerging specialty ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth ...

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new ...

Self-Development Model Prioritizing Equity Unlike traditional developments, Woodlawn Central is being self-developed by ACOG Ventures, the LLC entity of the Apostolic Church of God (ACOG), to ...

From medications to neuromodulation, lifestyle changes, and emerging therapies, understand the latest evidence and best practices for managing mental illness in pregnancy and postpartum.

By being educated about the risks associated with obesity and pregnancy, you can take some powerful steps today to begin minimizing yours.

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated ... with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil ...